For research use only
| Cat No. | ABC-TC0069 |
| Product Type | Human Leukemia Cell Lines |
| Cell Type | Lymphocyte-like |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Peripheral Blood |
| Disease | Acute Lymphoblastic Leukemia |
| Product Code | Ball-1; Ball 1; BALL1; B-cell Acute Lymphoblastic Leukemia-1 |
BALL-1 human B cells from leukemia patient show lymphoblast morphology, induce eosinophil chemotaxis, and are susceptible to abrin-a cytotoxic effects.
The BALL-1 cell line is derived from the peripheral blood of a patient with B-cell acute lymphoblastic leukemia (B-ALL). BALL-1 exhibit lymphoblast-like morphology and suspension culture properties. It exhibits unique characteristics, including its ability to induce T cells to produce a distinctive eosinophil chemotactic factor. Transplantation into immunodeficient hamsters results in aggressive infiltration of skin and bone marrow, rapid tumor growth, and eventual leukemia development. BALL-1 cells are susceptible to the cytotoxic effects of the lectin abrin-a, while the protein GPSM1 promotes tumor growth within the cell line. Cultures can be sustained through fresh medium supplementation or by subcultivation through centrifugation and subsequent resuspension.
| Product Code | Ball-1; Ball 1; BALL1; B-cell Acute Lymphoblastic Leukemia-1 |
| Species | Human |
| Cat.No | ABC-TC0069 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Lymphocyte-like |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Peripheral Blood |
| Disease | Acute Lymphoblastic Leukemia |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Leukemia Cell Lines |
The BALL-1 cell line emerges as a vital resource in immunological research and the advancement of precise treatments for acute lymphoblastic leukemia. Its relevance extends to serving as a model for pinpointing novel therapeutic targets within this context. By leveraging its unique characteristics, researchers can potentially formulate inhibitors or drugs that effectively differentiate human leukemic cells, thus holding promise for both laboratory investigations and future clinical applications.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
